On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
AMCP has recently published a manuscript in the Journal of Managed Care + Specialty Pharmacy (JMCP) focusing on the significant role that health plans, managed care organizations, prescribers, pharmacists, patients, and others have in decreasing the morbidity and mortality associated with opioid overdose.
AMCP Publishes New Pay-for-Performance Principles; AMCP Joins Public Health Leaders in Defense of OSHA’s COVID-19 Vaccine Rule; AMCP Supports Dr. Robert Califf’s Nomination for FDA Commissioner; ICYMI: AMCP Quarterly Legislative and Regulatory Briefing Now Available; Reps. DeGette and Upton Release the Cures 2.0 Act; AMCP Seeking New Regulatory Affairs Director.
AMCP Submits Comments on PDUFA; AMCP Joins Influenza Antiviral Sign-on Letter; AMCP Joins COVID-19 Antiviral Recommendations Sign-on Letter; President Biden Signs Infrastructure Investment and Jobs Act; President Biden To Nominate Dr. Robert Califf for FDA Commissioner.
AMCP Celebrates Grassroots Advocates at Nexus 2021; Congress Passes Continuing Resolution to Avoid Government Shutdown; Raises Debt Ceiling to Avert Default; FDA and CDC Approve Pfizer Booster; CMS Releases 2022 Premiums and Cost-Sharing Information for Medicare Advantage & Part D Plans; CMS Releases MA, Part D Star Ratings for 2022; MACPAC Report on Medicaid Churn.
Join us for a Grassroots Reception at Nexus 2021; Expanding Access to COVID-19 Therapeutics –HHS PREP Act Declaration: Ninth Amendment; HHS Comprehensive Plan for Addressing High Drug Prices; AMCP Virtual Legislative Days 2021; ICYMI: Respond to AMCP Policy Action Items Survey; AMCP Urges Congress to Implement Continuous Eligibility for Children in Medicaid and CHIP.